Earnings Releases·Nov 9, 2026, 7:00 AM ET

ProKidney — Q3 2026 Earnings Summary

**Financial Position:** Maintains a clean balance sheet with $142 million in cash, cash equivalents, and marketable securities as of September 30, 2026, providing a runway to support operations into mid-2027; no specific revenue or earnings figures were disclosed.
**Clinical Milestones:** Phase 3 PROACT 1 enrollment is projected to exceed 500 patients by Q1 2027, with a top-line readout for the accelerated approval surrogate endpoint (eGFR slope) expected in Q2 2027 and a BLA submission targeted for Q1 2028.
**Commercialization Timeline:** The company projects a BLA accelerated approval and commercial launch for rilparencel in the first half of 2029, contingent on the confirmatory endpoint readout expected in the second half of 2029.
**Manufacturing & Strategy:** The first phase of the North Carolina facility expansion was substantially completed in late 2026 with a second phase planned for 2027, supporting a phased rollout strategy starting with 10-20 high-density treatment centers.